Waterfront Wealth Inc. Sells 507 Shares of Edwards Lifesciences Corporation $EW

Waterfront Wealth Inc. trimmed its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 3.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,401 shares of the medical research company’s stock after selling 507 shares during the quarter. Waterfront Wealth Inc.’s holdings in Edwards Lifesciences were worth $1,205,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Jennison Associates LLC raised its holdings in shares of Edwards Lifesciences by 15.7% in the second quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock valued at $912,788,000 after acquiring an additional 1,584,958 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Edwards Lifesciences by 4.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock worth $491,673,000 after purchasing an additional 264,311 shares in the last quarter. Nuveen LLC bought a new position in Edwards Lifesciences in the first quarter worth about $330,881,000. Invesco Ltd. raised its holdings in Edwards Lifesciences by 2.6% in the first quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock worth $310,773,000 after purchasing an additional 107,241 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Edwards Lifesciences by 5.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock worth $287,140,000 after purchasing an additional 198,882 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.34% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have commented on EW shares. Stifel Nicolaus set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Monday, September 22nd. Wall Street Zen lowered Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Mizuho boosted their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Robert W. Baird boosted their price target on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a “neutral” rating in a research note on Friday, July 25th. Finally, Oppenheimer lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus target price of $87.89.

Edwards Lifesciences Trading Up 1.8%

Edwards Lifesciences stock opened at $82.26 on Wednesday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $83.25. The company has a market capitalization of $48.29 billion, a price-to-earnings ratio of 11.84, a price-to-earnings-growth ratio of 3.88 and a beta of 1.05. The stock has a 50-day moving average price of $77.49 and a 200 day moving average price of $76.65.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.